Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

6 Jun 2018 07:00

RNS Number : 4052Q
Instem plc
06 June 2018
 

6 June 2018

Instem plc

("Instem")

 

Contract win

 

Leading Fortune 500 Company adopts Instem's Samarind RMS solution for its worldwide medical products regulatory tracking system

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that a leading Fortune 500 medical products and pharmaceuticals company has adopted Instem's Samarind RMS Software-as-a-Service ("SaaS") solution. The contract is worth approximately US$750,000 incorporating both perpetual license and SaaS revenue streams with c. 80% of the contract value being recognised in 2018 and annual recurring revenue of US$169,000.

 

Samarind RMS provides medical device and pharmaceutical companies with a smarter way to manage their Product Information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. The product is optimised to enable these companies to register and track their regulated products worldwide by maintaining a single integrated database of all relevant information, which is then used to update regulators as products change over time. The comprehensive functionality provided by Samarind RMS enables customers to systematically define and execute complex regulatory activities across a globally dispersed workforce whilst providing a single place to find, analyse and act on a wealth of product and regulatory information.

 

Phil Reason, CEO of Instem plc, said: "This contract win with a global company, which ranks among the top 25 on the Fortune 500, continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field. We are very pleased to be delivering this as a SaaS agreement."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKPDKABKDAAK
Date   Source Headline
15th Nov 20191:10 pmRNSCompletion of the Acquisition of Leadscope
15th Nov 20197:00 amRNSEarnings Enhancing Acquisition of Leadscope
16th Oct 20197:00 amRNSInformatics Update: Progressive Equity Note
1st Oct 201910:20 amRNSHolding(s) in Company
27th Sep 201912:45 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSHalf-year Report
13th Sep 20197:00 amRNSNotice of Results
15th Jul 20197:00 amRNSHalf Year Trading Update
3rd Jun 20195:06 pmRNSDirector/PDMR Shareholding
31st May 20197:37 amRNSHolding(s) in Company
24th May 20195:03 pmRNSDirector/PDMR Shareholding
23rd May 201911:26 amRNSResult of AGM
2nd May 20194:47 pmRNSPosting of Annual Report & Notice of AGM
29th Apr 20197:00 amRNSExercise of Options and Total Voting Rights
26th Apr 201910:59 amRNSHolding(s) in Company
18th Apr 20192:06 pmRNSSecond Price Monitoring Extn
18th Apr 20192:00 pmRNSPrice Monitoring Extension
15th Apr 20196:03 pmRNSHolding(s) in Company
15th Apr 20195:00 pmRNSHolding(s) in Company
12th Apr 20193:46 pmRNSHolding(s) in Company
12th Apr 201911:58 amRNSHolding(s) in Company
12th Apr 201911:52 amRNSHolding(s) in Company
12th Apr 20197:36 amRNSHolding(s) in Company
11th Apr 20199:49 amRNSResult of Secondary Placing
11th Apr 20197:00 amRNSProposed Placing to Sell 1,660,000 Shares
8th Apr 20196:01 pmRNSHolding(s) in Company
4th Apr 20191:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFinal Results
20th Mar 20197:00 amRNSNotice of Results
1st Mar 20195:50 pmRNSHolding(s) in Company
1st Mar 20197:00 amRNSHolding(s) in Company
28th Feb 201910:35 amRNSIssue of Equity and Total Voting Rights
20th Feb 20191:44 pmRNSExercise of Options, PDMR Dealing and TVR
19th Feb 20192:09 pmRNSDirector/PDMR Shareholding
22nd Jan 20197:00 amRNSTrading Update
7th Dec 20183:28 pmRNSHolding(s) in Company
2nd Oct 20187:00 amRNSExercise of Options and Total Voting Rights
24th Sep 20187:00 amRNSHalf-year Report
10th Sep 20187:00 amRNSNotice of Results
6th Aug 20181:39 pmRNSHolding(s) in Company
23rd Jul 20187:00 amRNSTrading Update
6th Jun 20187:00 amRNSContract win
24th May 201810:43 amRNSResult of AGM
16th May 20183:18 pmRNSNotice of AGM
26th Mar 20187:01 amRNSSEND Contract Extension and SEND Update
26th Mar 20187:00 amRNSFinal Results
16th Mar 20187:00 amRNSNotice of Results
12th Mar 20189:33 amRNSIssue of Equity and TVR
7th Mar 20187:00 amRNSSaaS Business Update
26th Feb 20187:00 amRNSGrants to Directors under the Instem LTIP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.